Durect Corp (FRA:DC8A)
€ 0.785 -0.015 (-1.88%) Market Cap: 25.87 Mil Enterprise Value: 29.05 Mil PE Ratio: 0 PB Ratio: 22.56 GF Score: 60/100

DURECT Corporation - Special Call Transcript

Feb 27, 2019 / 03:30PM GMT
Release Date Price: €7.05 (-0.56%)
Operator

Good day, ladies and gentlemen, and welcome to the POSIMIR and KOL call hosted by the DURECT Corporation. As a reminder, today's conference is being recorded.

At this time, I'd like to turn the conference over to Mr. Mike Arenberg. Please go ahead, sir.

Michael H. Arenberg
DURECT Corporation - CFO

Thank you. Good morning, and welcome to our conference call to provide an update on our POSIMIR program. This is Mike Arenberg, Chief Financial Officer of DURECT Corporation. This call will begin with some introductory remarks by Jim Brown, our President and CEO; and then we will hear from Dr. Lee Simon, who has been leading the process we have undertaken with respect to POSIMIR. We will then open up the call for a question-and-answer session.

Before beginning, I would like to remind you of our safe harbor statement. During the course of this call, we may make forward-looking statements regarding DURECT products and development, expected product benefits, our development plans, future clinical trials or projected financial results. These forward

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot